Follow‑up care after COVID-19 and its related concerns

Czech version

Authors: Martin Radvan ^1,6; Elis Bartečků ^2,6; Ubica Sýkorová ^3,6; Radana Pařízková ^4,6; Svatopluk Richter ^5,6; Martin Kameník ^1,6; Lumír Koc ^1,6; Petr Kala ^1,6
Authors‘ workplace: Interní kardiologická klinika FN Brno ¹; Psychiatrická klinika FN Brno ²; Klinika nemocí plicních a tuberkulózy FN Brno ³; Infekční klinika FN Brno ⁴; Klinika radiologie a nukleární medicíny FN Brno ⁵; Lékařská fakulta Masarykovy univerzity ⁶
Published in: Vnitř Lék 2021; 67(1): 30-36
Category:

Overview

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Overall COVID-19-related rates of mortality are low; deaths usually occur in patients older than 60 and those suffering from serious chronic diseases. Most of the patients recover within one or two weeks. However, in approximately 5–10 % of the patients some of the symptoms persist for weeks and months. Post-COVID-19 syndrome is a multisystem disease with overlapping symptoms and may occur even in patients who were relatively mildly affected during the acute phase of the disease. Evaluating the number of patients with or after the novel coronavirus infection in the Czech Republic, it can be estimated that in the next months there will be about 50,000 new patients suffering from long-COVID-19 requiring attention of general practitioners in the least, and, in all probability, also of other medical specialists. A thorough knowledge of the syndrome and efficient ideally evidence-based guidelines have to be formulated to combat the adverse impact of the pandemic.

Keywords:

COVID-19 – SARS -CoV-2 – long -COVID-19 – post -COVID-19 syndrome – follow -up

Sources

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7; 323(13): 1239–1242. Dostupné z DOI:

2. Streeck H, Hartmann G, Exner M et al. Universitätsklinikum Bonn, 09. 04. 2020. Dostup‑ né z DOI: https://www.land.nrw/sites/default/files/asset/document/zwischenergebnis_ covid19_case_study_gangelt_0.pdf.

3. Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed 2020; 91(3-s): 175–159

4. Dostupné z DOI: https://onemocneni‑aktualne.mzcr.cz/covid-19. 5. Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383(27): 2603– 2615. Dostupné z DOI:

5. Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and Effica‑ cy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383(27): 2603– 2615. Dostupné z DOI:

6. Haake D. Gangelt – A representative study on the lethality of COVID-19. Dostupné z DOI:

7. Ioannidis JPA, Cathrine Axfors C, Despina G. et al. Population‑level COVID-19 mortality risk for non‑elderly individuals overall and for nonelderly individuals without underlying diseases in pandemic epicenters: medRxiv 2020. 04. 05.20054361; Dostupné z DOI: htt‑ ps://doi.org/10.1101/2020. 04. 05.2005.

8. Qingxian Cai, DeliangHuang, HongYu, et al. COVID-19: Abnormal liver functi‑ on tests Journal of Hepatology, 2020, ISSN 0168-8278, https://doi.org/10.1016/j. jhep.2020. 04. 006.

9. Klok FA et al., Incidence of thrombotic complications in critically ill ICU patients with CO‑ VID-19 Thrombosis Research, Dostupné z DOI: https://doi.org/10.1016/j.thromres.2020. 04. 013

10. Oxley et al. Large‑Vessel Stroke as a Presenting Feature of Covid-19 in the Young NEJM April 28, 2020, Dostupné z DOI: 10.1056/NEJMc2009787.

11. Mechl M., Júza T, Hodová S. CT vyšetření hrudníku u pacientů s onemocněním CO‑ VID-19 – první zkušenosti, Ces Radiol 2020; 74(3): 189–195.

12. Dostupné z DOI: www.pneumologie.cz.

13. Dostupné z DOI: www.crs.cz.

14. George PM, Barratt SL, Condliffe R et al. Respiratory follow‑up of patients with CO‑ VID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-1016. Dostupné z DOI: doi: 10.1136/tho‑ raxjnl-2020-215314. Epub 2020 Aug 24.

15. National Guidance for post‑COVID syndrome assessment clinics Dostupné z DOI: htt‑ ps://www.england.nhs.uk/coronavirus/wp‑content/uploads/sites/52/2020/10/C0840_ PostCOVID_assessment_clinic_guidance_5_Nov_2020.pdf.

16. COVID-19 guideline scope: management of the long‑term effects of COVID-19 NICE, SIGN, RCGP Dostupné z DOI: https://www.nice.org.uk/guidance/gid‑ng10179/documents/final‑scope

17. Carfì A, Bernabei R, Landi F. Gemelli Against COVID-19 Post‑Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; Dostupné z DOI: doi: 10.1001/jama.2020.12603 pmid: 32644129

18. Tenforde MW, Kim SS, Lindsell CJ et al. IVY Network InvestigatorsCDC COVID-19 Response TeamIVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March‑June 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 993–998.

19. Petrie JG, Cheng C, Malosh RE, et al. Illness severity and work productivity loss among working adults with medically attended acute respiratory illnesses: US Influenza Vaccine Effectiveness Network 2012–2013. Clin Infect Dis 2016; 62: 448–455.

20. Kopecký, Skála, Šnelerová et al. Post‑COVID syndrom – definice, diagnostika a klasifi‑ kace, stručný poziční dokument ČPFS ČLS JEP (leden 2021) Dostupné z DOI: http://www. pneumologie.cz/novinka/1755/post‑covid‑syndrom‑definice‑diagnostika‑a-klasifikace‑ ‑strucny‑pozicni‑dokument/

21. Puntmann VO, Carerj ML, Wieters I et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Nov 1; 5(11): 1265–1273. Dostupné z DOI: doi: 10.1001/jama‑ cardio.2020.3557. PMID: 32730619; PMCID: PMC7385689.

22. Malas MB, Naazie IN, Elsayed N et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta‑analysis. EClinicalMedicine. 2020; 29:100639 (ISSN 2589-5370)

23. Moores LK, Tritschler T, Brosnahan S et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020; 158(3): 1143–1163. Dostupné z DOI: doi:10.1016/j.chest.2020. 05. 559

24. Troyer E, Jokn J, Hong KS. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms Brain Behavior and Immunity. April 2020. 87 Dostupné z DOI: 10.1016/j.bbi.2020. 04. 027

25. KS‑S Leung, TT‑L Ng, AK‑L Wu et al. A territory‑wide study of early COVID-19 outbreak in Hong Kong community: a clinical, epidemiological and phylogenomic investigation medRxiv (2020) published online April 7. Dostupné z DOI: 10.1101/2020. 03. 30.20045740

26. Helms J, Kremer S, Merdji H, Clere‑Jehl R et al. Neurologic Features in Severe SARS‑CoV-2 Infection. N Engl J Med. 2020 Jun 4; 382(23): 2268–2270. Dostupné z DOI: doi: 10.1056/ NEJMc2008597. Epub 2020 Apr 15. PMID: 32294339; PMCID: PMC7179967.

27. Zazzara MB, Penfold RS, Roberts AL et al. Probable delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community‑based older adults. Age Ageing. 2020 Sep 28:afaa223. Dostupné z DOI: doi: 10.1093/ageing/ afaa223. Epub ahead of print. PMID: 32986799; PMCID: PMC7543251.